NO plays a role in LPS-induced decreases in circulating IGF-I and IGFBP-3 and their gene expression in the liver 

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author Priego, Teresa
dc.contributor.author Ibáñez de Cáceres, Inmaculada
dc.contributor.author Martín, Ana Isabel
dc.contributor.author Villanúa, María de los Ángeles
dc.contributor.author López-Calderón, Asunción
dc.date.accessioned 2016-08-22T09:01:34Z
dc.date.available 2016-08-22T09:01:34Z
dc.date.issued 2004
dc.identifier.citation Priego, T., Ibañez de Cáceres, I., Martín Velasco, A. I., Villanúa, M. A., & López-Calderón, A. (2004). NO plays a role in LPS-induced decreases in circulating IGF-I and IGFBP-3 and their gene expression in the liver. American Journal of Physiology - Endocrinology and Metabolism, 286(1), E50-E56. spa
dc.identifier.issn 01931849
dc.identifier.uri http://hdl.handle.net/11268/5650
dc.description.abstract In this study, we administered aminoguanidine, a relatively selective inducible nitric oxide synthase (iNOS) inhibitor, to study the role of nitric oxide (NO) in LPS-induced decrease in IGF-1 and IGFBP-3. Adult male Wistar rats were injected intraperitoneally with LPS (100 μg/kg), aminoguanidine (100 μg/kg), LPS plus aminoguanidine, or saline. Rats were injected at 1730 and 0830 the next day and killed 4 h after the last injection. LPS administration induced an increase in serum concentrations of nitrite/nitrate (P < 0.01) and a decrease in serum concentrations of growth hormone (GH; P < 0.05) and IGF-I (P < 0.01) as well as in liver IGF-I mRNA levels (P < 0.05). The LPS-induced decrease in serum concentrations of IGF-I and liver IGF-I gene expression seems to be secondary to iNOS activation, since aminoguanidine administration prevented the effect of LPS on circulating IGF-I and its gene expression in the liver. In contrast, LPS-induced decrease in serum GH was not prevented by aminoguanidine administration. LPS injection decreased IGFBP-3 circulating levels (P < 0.05) and its hepatic gene expression (P < 0.01), but endotoxin did not modify the serum IGFBP-3 proteolysis rate. Aminoguanidine administration blocked the inhibitory effect of LPS on both IGFBP-3 serum levels and its hepatic mRNA levels. When aminoguanidine was administered alone, IGFBP-3 serum levels were increased (P < 0.05), whereas its hepatic mRNA levels were decreased. This contrast can be explained by the decrease (P < 0.05) in serum proteolysis of this binding protein caused by aminoguanidine. These data suggest that iNOS plays an important role in LPS-induced decrease in circulating IGF-I and IGFBP-3 by reducing IGF-I and IGFBP-3 gene expression in the liver. spa
dc.description.sponsorship SIN FINANCIACIÓN spa
dc.language.iso eng spa
dc.title NO plays a role in LPS-induced decreases in circulating IGF-I and IGFBP-3 and their gene expression in the liver  spa
dc.type article spa
dc.description.impact 4.431 JCR (2004) Q1, 6/74 Physiology, 16/87 Endocrinology & metabolism spa
dc.identifier.doi 10.1152/ajpendo.00149.2003 spa
dc.rights.accessRights closedAccess spa
dc.subject.uem Fisiología humana spa
dc.subject.uem Endocrinología spa
dc.subject.uem Metabolismo - Enfermedades spa
dc.subject.unesco Fisiología spa
dc.subject.unesco Sistema endocrino spa
dc.subject.unesco Enfermedad nutricional spa
dc.description.filiation UEM spa
dc.peerreviewed Si spa

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record